Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) operates at the intersection of scientific instrumentation and laboratory workflows, making its news coverage particularly relevant for investors tracking the life sciences and diagnostics sectors. As a major supplier to pharmaceutical, environmental, and clinical laboratories worldwide, Agilent's announcements often signal broader trends in research spending and healthcare diagnostics.
Key news categories for Agilent include quarterly earnings reports that reveal demand across its three business segments, product launches introducing new chromatography systems, mass spectrometers, and diagnostic assays, and FDA regulatory decisions affecting its companion diagnostics products. The company's pathology and genomics solutions frequently receive clearances that expand clinical testing capabilities.
Investors also monitor Agilent for strategic collaborations with pharmaceutical and biotechnology companies, acquisitions that extend its technology portfolio, and announcements regarding its dividend program. Conference presentations at healthcare investor events provide management perspectives on end-market conditions in biopharma, food testing, and environmental analysis.
Agilent's news flow reflects its position serving regulated industries where instrument qualification, method validation, and compliance software are critical. Product announcements often highlight improvements in analytical sensitivity, throughput, and data integrity features that laboratories require for regulatory submissions.
Bookmark this page to follow Agilent Technologies developments as they happen, from earnings releases and product innovations to partnerships shaping the future of analytical science.
Lunit (KRX:328130.KQ) and Agilent (NYSE:A) announced a nonexclusive collaboration on Sept 22, 2025 to co-develop AI-powered companion diagnostic (CDx) solutions for complex biomarker assays.
The partnership will combine Lunit's AI algorithms and Agilent's tissue-based diagnostic assays, initially targeting research and clinical-trial use to improve biomarker accuracy and support pharma CDx development. Lunit noted its FDA-cleared Lunit INSIGHT suite is used at over 7,000 medical institutions in more than 65 countries.
TORM (NASDAQ: TRMD A) increased share capital on Nov 14, 2025 by 970,646 A-shares following exercise of Restricted Share Units (RSUs), corresponding to a nominal USD 9,706.46.
Of the new shares, 963,146 were subscribed in cash at DKK 0.07 per A-share and 7,500 at DKK 140.2 per share. The issuance was carried out without pre-emption rights. After the increase, share capital amounts to USD 1,013,185.03 divided into 101,318,501 A-shares, plus one B-share and one C-share. New shares are ordinary, carry dividend rights as of issuance, and are expected to be listed on Nasdaq Copenhagen.
TORM plc (A) reported director share transactions by CEO Jacob Balslev Meldgaard related to exercise of restricted share units in November 2025.
The exercises occurred 12 November 2025 and 14 November 2025, totaling 585,473 shares (ISIN GB00BZ3CNK81) with an aggregated value of DKK 11,961,321.62. The transactions were executed outside a trading venue. Contact for the filing is Head of Investor Relations Mikael Bo Larsen.
Agilent (NYSE: A) awarded an Agilent Research Catalyst (ARC) grant to the University of California, Davis on behalf of Professor Marie Heffern on November 12, 2025.
The award funds research using Agilent instrumentation (8900 ICP-QQQ, 6546 Q-TOF LC/MS, Infinity II LC) to study metal–peptide interactions in incretin-based therapeutics (GLP-1 receptor agonists). The project will apply LC-ICP-MS, native MS, and high-resolution peptide mapping to assess effects on drug stability, formulation, and bioactivity, aiming to build a predictive framework to inform formulation strategies and reduce degradation.
TORM plc (NASDAQ: TRMD / TRMD A) completed a capital increase of 2,395,426 A-shares (nominal USD 23,954.26) on Nov 12, 2025 related to delivery of one LR2 vessel and exercise of Restricted Share Units (RSUs).
Key items: 748,569 shares were issued to settle a USD 17.0m allocated loan note for the 2010-built LR2 (USD 22.71 per A-share). 1,646,857 A-shares were issued on RSU exercises (1,558,790 at DKK 0.07 and 88,067 at DKK 140.2). New shares are subject to a 40-day lock-up with Regulation S resale exceptions.
Post-increase share capital: USD 1,003,478.57 divided into 100,347,855 A-shares, one B-share and one C-share.
Helzberg (NYSE:A) will open redesigned stores in New York and Dallas in November 2025, unveiling next‑generation brick-and-mortar concepts that combine digital discovery with hands-on craftsmanship. The new stores feature an interactive custom bar, a visible jeweler's workshop, a larger diamond carat-weight assortment in engagement rings and wedding bands, and an expanded Luxe Jewelry collection.
A company consumer study found 83% of couples say the ability to purchase in-store is important, nearly three in five plan to consult a jeweler and buy in person, 47% rate ring customization as very important, and 76% would invest more in a custom design. Helzberg also highlights digital support via its Love & Marriage Studio for pre-visit education and inspiration.
Crawford & Company (NYSE: CRD-A, CRD-B) announced that on October 30, 2025 its Board authorized an additional 2.0 million shares under its existing share repurchase program and extended the program termination to December 31, 2027. The repurchase program, originally approved November 4, 2021 and increased February 10, 2022, had authorized up to an aggregate of seven million common shares; as of October 30, 2025 only 634,920 shares remained under that authorization. Repurchases may occur in the open market or via privately negotiated transactions and are discretionary. The Board also declared a quarterly dividend of $0.075 per share, payable December 5, 2025 to shareholders of record as of November 19, 2025.
Agilent (NYSE: A) will release fourth-quarter fiscal 2025 results after market close on Monday, Nov. 24, 2025. The company will host a listen-only conference call webcast at 1:30 p.m. PST the same day, with a recording available on Agilent's investor website for 90 days.
Agilent reported $6.51 billion revenue in fiscal 2024 and employs approximately 18,000 people. Webcast access is via the Events section of Agilent's Investor Relations site; investor and media contacts are provided for follow-up.
Agilent (NYSE: A) named Adam S. Elinoff as chief financial officer, effective Nov. 17, 2025. Elinoff joins from Amgen after 19 years, most recently serving as vice president of finance and treasurer, and previously managing a $6 billion P&L across 67 markets as regional CFO. Agilent reported $6.51 billion revenue for fiscal 2024. Rodney Gonsalves will return to his role as corporate controller and principal accounting officer.
The appointment emphasizes Elinoff’s experience in finance, strategy, M&A, and global transformations as Agilent executes its Ignite Operating System.
Helzberg, a Berkshire Hathaway company (NYSE: BRK), released its 2025 Engagement & Ring Shopping Survey revealing key trends in modern proposals and ring shopping behaviors. The study, surveying 1,000 U.S. adults aged 20-40, found that 83% prefer private proposals, despite 88% planning to share ring preferences beforehand.
The survey highlighted significant generational differences, with Gen Z showing stronger engagement in social media research (79% vs. 63% millennials) and sustainability concerns (88% vs. 81%). Notable findings include an average maximum ring budget of $4,000, with 76% willing to invest more for customization. While 83% value in-store purchasing options, 56% consider online buying important, reflecting evolving shopping preferences.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
